Polewaczyk F. James's Insider Trades & SAST Disclosures
Polewaczyk F. James's most recent trade in Idexx Laboratories, Inc. was a trade of 4,640 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on March 6, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Polewaczyk F. James.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 4,640 | 1,363 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 544.08 per share. | 06 Mar 2024 | 4,640 | 18,815 (0%) | 0% | 544.1 | 2,524,531 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 557.94 per share. | 06 Mar 2024 | 4,134 | 14,681 (0%) | 0% | 557.9 | 2,306,528 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 558.88 per share. | 06 Mar 2024 | 3,290 | 11,391 (0%) | 0% | 558.9 | 1,838,722 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 2,226 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 288.78 per share. | 06 Mar 2024 | 2,226 | 14,175 (0%) | 0% | 288.8 | 642,824 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 06 Mar 2024 | 755 | 11,466 (0%) | 0% | 206.9 | 156,240 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 755 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 559.33 per share. | 06 Mar 2024 | 680 | 10,711 (0%) | 0% | 559.3 | 380,346 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 06 Mar 2024 | 483 | 11,949 (0%) | 0% | 206.9 | 99,952 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 483 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Polewaczyk James F. | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 279 | 10,711 (0%) | 0% | 560.6 | 156,396 | Common Stock |
| Idexx Laboratories, Inc. | F. James Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 220 | 660 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 220 | 10,990 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Polewaczyk F. James | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 216 | 10,405 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Polewaczyk James F. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 216 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | F. James Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 204 | 10,770 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Polewaczyk F. James | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 204 | 408 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 161 | 160 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Polewaczyk F. James | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 161 | 10,566 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Polewaczyk James F. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 126 | 10,189 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Polewaczyk James F. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 126 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Polewaczyk F. James | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 6,680 | 2,226 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James Polewaczyk F. | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 288.78 per share. | 07 Dec 2023 | 6,680 | 21,685 (0%) | 0% | 288.8 | 1,929,050 | Common Stock |
| Idexx Laboratories, Inc. | F. Polewaczyk James | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 4,956 | 755 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 07 Dec 2023 | 4,956 | 15,005 (0%) | 0% | 206.9 | 1,025,595 | Common Stock |
| Idexx Laboratories, Inc. | F. James Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 523.56 per share. | 07 Dec 2023 | 3,940 | 10,049 (0%) | 0% | 523.6 | 2,062,812 | Common Stock |
| Idexx Laboratories, Inc. | F. James Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 521.00 per share. | 07 Dec 2023 | 3,378 | 15,191 (0%) | 0% | 521.0 | 1,759,954 | Common Stock |
| Idexx Laboratories, Inc. | F. James Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 520.19 per share. | 07 Dec 2023 | 3,116 | 18,569 (0%) | 0% | 520.2 | 1,620,919 | Common Stock |
| Idexx Laboratories, Inc. | Polewaczyk James F. | Executive Vice President | Sale of securities on an exchange or to another person at price $ 522.31 per share. | 07 Dec 2023 | 1,202 | 13,989 (0%) | 0% | 522.3 | 627,816 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 511.03 per share. | 29 Aug 2023 | 7,473 | 12,924 (0%) | 0% | 511.0 | 3,818,917 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 7,151 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 29 Aug 2023 | 7,151 | 26,521 (0%) | 0% | 141.6 | 1,012,582 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 510.38 per share. | 29 Aug 2023 | 6,186 | 23,715 (0%) | 0% | 510.4 | 3,157,196 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 5,865 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 29 Aug 2023 | 5,865 | 32,946 (0%) | 0% | 178.3 | 1,045,495 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 510.47 per share. | 29 Aug 2023 | 3,318 | 20,397 (0%) | 0% | 510.5 | 1,693,728 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 511.22 per share. | 29 Aug 2023 | 2,887 | 10,037 (0%) | 0% | 511.2 | 1,475,903 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.75 per share. | 29 Aug 2023 | 2,627 | 18,664 (0%) | 0% | 68.7 | 180,606 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 2,627 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 509.32 per share. | 29 Aug 2023 | 2,545 | 29,901 (0%) | 0% | 509.3 | 1,296,221 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 706 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 29 Aug 2023 | 706 | 19,370 (0%) | 0% | 141.6 | 99,970 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 560 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 29 Aug 2023 | 560 | 27,081 (0%) | 0% | 178.3 | 99,826 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 508.96 per share. | 29 Aug 2023 | 500 | 32,446 (0%) | 0% | 509.0 | 254,482 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 503.65 per share. | 14 Feb 2023 | 252 | 16,011 (0%) | 0% | 503.7 | 126,920 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 216 | 15,898 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 216 | 2,520 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 204 | 2,155 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 204 | 16,263 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 161 | 16,605 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 161 | 2,359 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 127 | 15,682 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 127 | 2,736 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 126 | 15,555 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 126 | 2,863 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 6,236 | 6,236 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 880 | 2,989 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 201 | 201 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 7,009 | 7,009 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 816 | 2,890 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 505.53 per share. | 14 Feb 2022 | 235 | 15,374 (0%) | 0% | 505.5 | 118,800 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 217 | 2,270 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 217 | 15,448 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 197 | 197 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 161 | 2,109 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 161 | 15,609 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 150 | 2,740 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 150 | 14,978 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 127 | 2,487 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 127 | 15,231 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 126 | 2,614 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 126 | 15,104 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 633.00 per share. | 29 Nov 2021 | 4,595 | 14,818 (0%) | 0% | 633 | 2,908,635 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Aug 2021 | 522 | 19,494 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 10,000 | 2,627 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 28 May 2021 | 10,000 | 29,915 (0%) | 0% | 67.9 | 678,500 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 562.65 per share. | 28 May 2021 | 2,462 | 22,341 (0%) | 0% | 562.7 | 1,385,253 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 564.04 per share. | 28 May 2021 | 1,713 | 20,628 (0%) | 0% | 564.0 | 966,198 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 561.77 per share. | 28 May 2021 | 1,429 | 24,803 (0%) | 0% | 561.8 | 802,771 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 559.77 per share. | 28 May 2021 | 1,370 | 27,506 (0%) | 0% | 559.8 | 766,879 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 560.79 per share. | 28 May 2021 | 1,274 | 26,232 (0%) | 0% | 560.8 | 714,451 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 558.89 per share. | 28 May 2021 | 1,039 | 28,876 (0%) | 0% | 558.9 | 580,690 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 564.73 per share. | 28 May 2021 | 513 | 20,115 (0%) | 0% | 564.7 | 289,704 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Sale of securities on an exchange or to another person at price $ 565.56 per share. | 28 May 2021 | 200 | 19,915 (0%) | 0% | 565.6 | 113,111 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 1,476 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 25 Feb 2021 | 1,476 | 19,903 (0%) | 0% | 67.9 | 100,147 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 6,003 | 6,003 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 643 | 2,937 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 544.08 per share. | 14 Feb 2021 | 257 | 18,427 (0%) | 0% | 544.1 | 139,829 | Common Stock |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 243 | 2,694 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 243 | 18,064 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 217 | 18,684 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 217 | 2,074 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 183 | 183 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 150 | 2,544 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 150 | 18,214 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 127 | 2,291 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 127 | 18,467 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | James F. Polewaczyk | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 126 | 2,418 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges